AmerisourceBergen Elects Gregory D. Wasson to Its Board of Directors

  AmerisourceBergen Elects Gregory D. Wasson to Its Board of Directors

Business Wire

VALLEY FORGE, Pa. -- May 15, 2014

AmerisourceBergen Corporation (NYSE: ABC) today announced that Gregory D.
Wasson, President and Chief Executive Officer of Walgreen Co. (Walgreens)
(NYSE, Nasdaq: WAG), has been elected to its Board of Directors, effective
immediately. The election of Mr. Wasson expanded the Company’s Board of
Directors to 11 members. Mr. Wasson has not been appointed to serve on any
committees of the Board.

Walgreens was entitled to designate a director to the AmerisourceBergen Board
of Directors as part of the strategic long-term relationship the Company
entered into with Walgreens and Alliance Boots GmbH in March of 2013. “We are
very pleased to have Greg join the AmerisourceBergen Board of Directors,” said
Richard C. Gozon, Chairman of the Board of AmerisourceBergen. “His extensive
healthcare experience, strategic vision, and commitment to working
collaboratively to drive growth and shareholder value for both
AmerisourceBergen and Walgreens, will make Greg a tremendous asset to the
Board.”

“I am thrilled to have Greg join our Board of Directors,” added Steven H.
Collis, President and Chief Executive Officer of AmerisourceBergen. “With his
innovative insights, long-standing commitment to community pharmacy, and
demonstrated partnership philosophy, I am certain that Greg will make valuable
contributions to our Board.”

Mr. Wasson is currently the President and Chief Executive Officer of
Walgreens, and has served on the Walgreens board of directors since 2009. A
graduate of Purdue University’s School of Pharmacy, Mr. Wasson has served in a
number of senior management and executive positions throughout his 33-year
career with Walgreens, including President and Chief Operating Officer of
Walgreens from May 2007 to February 2009, Executive Vice President from
October 2005 to May 2007, Senior Vice President from February 2004 to October
2005 and Vice President from October 2001 to February 2004. He was also
President of Walgreens Health Services from March 2002 to May 2007. Mr. Wasson
has served as a director of Alliance Boots GmbH since August 2012 and of
Verizon Communications, Inc. since March 2013.

About AmerisourceBergen

AmerisourceBergen is one of the largest global pharmaceutical sourcing and
distribution services companies, helping both healthcare providers and
pharmaceutical and biotech manufacturers improve patient access to products
and enhance patient care. With services ranging from drug distribution and
niche premium logistics to reimbursement and pharmaceutical consulting
services, AmerisourceBergen delivers innovative programs and solutions across
the pharmaceutical supply channel. With over $100 billion in annualized
revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs
approximately 13,000 people. AmerisourceBergen is ranked #32 on the Fortune
500 list. For more information, go to www.amerisourcebergen.com.

AmerisourceBergen's Cautionary Note Regarding Forward-Looking Statements

Certain of the statements contained in this news release are “forward-looking
statements” within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934. Words such as
“expect,” “likely,” “outlook,” “forecast,” “would,” “could,” “should,” “can,”
“will,” “project," “intend,” “plan,” “continue,” “sustain,” “synergy,” “on
track,” “believe,” “seek,” “estimate,” “anticipate,” “may,” “possible,”
“assume,” variations of such words, and similar expressions are intended to
identify such forward-looking statements. These statements are based on
management’s current expectations and are subject to uncertainty and change in
circumstances. These statements are not guarantees of future performance and
are based on assumptions that could prove incorrect or could cause actual
results to vary materially from those indicated. Among the factors that could
cause actual results to differ materially from those projected, anticipated,
or implied are the following: changes in pharmaceutical market growth rates;
the loss of one or more key customer or supplier relationships; the retention
of key customer or supplier relationships under less favorable economics;
changes in customer mix; customer delinquencies, defaults or insolvencies;
supplier defaults or insolvencies; changes in branded and/or generic
pharmaceutical manufacturers’ pricing and distribution policies or practices;
adverse resolution of any contract or other dispute with customers or
suppliers; federal and state government enforcement initiatives to detect and
prevent suspicious orders of controlled substances and the diversion of
controlled substances, federal and state prosecution of alleged violations of
related laws and regulations, and any related litigation, including
shareholder derivative lawsuits or other disputes relating to our distribution
of controlled substances; qui tam litigation for alleged violations of fraud
and abuse laws and regulations and/or any other laws and regulations governing
the marketing, sale, purchase and/or dispensing of pharmaceutical products or
services and any related litigation, including shareholder derivative
lawsuits; changes in federal and state legislation or regulatory action
affecting pharmaceutical product pricing or reimbursement policies, including
under Medicaid and Medicare, and the effect of such changes on our customers;
changes in regulatory or clinical medical guidelines and/or labeling for the
pharmaceutical products we distribute; price inflation in branded and generic
pharmaceuticals and price deflation in generics; greater or less than
anticipated benefit from launches of the generic versions of previously
patented pharmaceutical products; significant breakdown or interruption of our
information technology systems; our inability to realize the anticipated
benefits of the implementation of an enterprise resource planning (ERP)
system; interest rate and foreign currency exchange rate fluctuations; risks
associated with international business operations, including non-compliance
with the U.S. Foreign Corrupt Practices Act, anti-bribery laws and economic
sanctions and import laws and regulations; economic, business, competitive
and/or regulatory developments in countries where we do business and/or
operate outside of the United States; risks associated with the strategic,
long-term relationship among Walgreen Co., Alliance Boots GmbH, and
AmerisourceBergen, the occurrence of any event, change or other circumstance
that could give rise to the termination, cross-termination or modification of
any of the transaction documents among the parties (including, among others,
the distribution agreement or the generics agreement), an impact on our
earnings per share resulting from the issuance of the Warrants, an inability
to realize anticipated benefits (including benefits resulting from
participation in the Walgreens Boots Alliance Development GmbH joint venture),
the disruption of AmerisourceBergen’s cash flow and ability to return value to
its stockholders in accordance with its past practices, disruption of or
changes in vendor, payer and customer relationships and terms, and the
reduction of AmerisourceBergen’s operational, strategic or financial
flexibility; the acquisition of businesses that do not perform as we expect or
that are difficult for us to integrate or control; our inability to
successfully complete any other transaction that we may wish to pursue from
time to time; changes in tax laws or legislative initiatives that could
adversely affect our tax positions and/or our tax liabilities or adverse
resolution of challenges to our tax positions; increased costs of maintaining,
or reductions in our ability to maintain, adequate liquidity and financing
sources; volatility and deterioration of the capital and credit markets;
natural disasters or other unexpected events that affect our operations; and
other economic, business, competitive, legal, tax, regulatory and/or
operational factors affecting our business generally. Certain additional
factors that management believes could cause actual outcomes and results to
differ materially from those described in forward-looking statements are set
forth (i) in Item 1A (Risk Factors) and Item 1 (Business) in the Company’s
Annual Report on Form 10-K for the fiscal year ended September 30, 2013 and
elsewhere in that report and (ii) in other reports.

Contact:

AmerisourceBergen Corporation
Barbara Brungess
Vice President, Corporate & Investor Relations
610-727-7199
bbrungess@amerisourcebergen.com
 
Press spacebar to pause and continue. Press esc to stop.